by Dr. C.H. Weaver M.D. updated 6/2021

Preliminary results from the Phase I study of talquetamab (JNJ-64407564), a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody therapy in development by Janssen, were presented on at the 2020 American Society of Hematology Annual Meeting and updated at the 2021 event. This early phase clinical study evaluated the safety and technical feasibility of talquetamab as a treatment for patients with progressive multiple myeloma.1

About Talquetamab (JNJ-64407564)

Talquetamab is a first-in-class investigational bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3, the T-cell receptor. CD3 is involved in activating T-cells and GPRC5D is highly expressed on multiple myeloma cells. The binding of both activates the immune system to attach the myeloma cells. Results from preclinical studies in mouse models demonstrate that talquetamab induces T-cell-mediated killing of GPRC5D-expressing multiple myeloma cells through the recruitment and activation of CD3-positive T-cells and inhibits tumor formation and growth. (2-5)

In the phase I trial 69% of refractory myeloma patients responded to treatment with 39% of patients achieving a very good or complete response. Talquetamab had moderate side effects. A low white blood count (neutropenia) occurred in 42% of the patients and Cytokine release syndrome (CRS) in 64%. The CRS was low-grade without associated mortality. Phase trial confirmed a 70% response rate in patients with advanced disease. 

These early results are encouraging, and the developer has announced that dose expansion is on-going and that a Phase II clinical trial for talquetamab is planned.

Recommended Articles

Image placeholder title

What Should Women Know About Bladder Cancer

Michael O’Donnell, MD Director of Urologic Oncology, University of Iowa Hospitals and Clinics

Green Background CC CancerConnect

Liquid Biopsy Detects Disease Progression Much Earlier Than Imaging

What if a simple blood test could quickly determine when chemotherapy was ineffective and prevent its unnecessary use?

References

  1. Abstract 290. ASH 2020. December 5, 2020. A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM).
  2. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
  3. Labrijn AF et al. Proc Natl Acad Sci USA. 2013;110:5145.
  4. Cohen, Y., et al. Hematology. 2013 Nov; 18(6):348-51d
  5. Kumar SK, et al. Leukemia. 2012 Jan; 26(1):149-57.